Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Search results for: “patient perspective”

  • Interview with Dara Corrigan, JD: United States to Implement Mutual Recognition Agreement with European Union

    Interview with Dara Corrigan, JD: United States to Implement Mutual Recognition Agreement with European Union

    By

    Regulatory Agency Perspective

    Posted: April 2017 *Erik T. MacLaren, PhD, is acknowledged for his editorial support of this article. On March 2, 2017, the European Union (EU) and the US announced the Mutual Recognition Agreement to allow the FDA and the EU to accept one another’s inspections of drug and pharmaceutical manufacturing facilities, a change intended to reduce…

  • Should Physicians Recommend E-Cigarettes to Their Lung Cancer Patients Who Smoke? What About Their Family Members Who Also Smoke?

    Should Physicians Recommend E-Cigarettes to Their Lung Cancer Patients Who Smoke? What About Their Family Members Who Also Smoke?

    By

    Tobacco Control & Smoking Cessation

    Posted: April 2017 Opinion-No: Emily Stone, MBBS, MMed There is little doubt that lung cancer patients and the people around them who smoke need to stop. Smoking cessation can improve survival,1 surgical outcomes,2-4 and response to anticancer therapies5 and can reduce the risk of recurrence.6 However, many physicians feel poorly trained and unsure about providing…

  • A Life in Thoracic Oncology – Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer

    A Life in Thoracic Oncology – Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer

    By

    Uncategorized

    Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC The closing plenary session at IASLC WCLC 2016 featured several highly regarded oncologists who have devoted the greater part of their careers to thoracic oncology. These “giants” reflected on their work and the changes they have seen in the key areas of chemotherapy, thoracic surgery, radiation…

  • Lung Cancer in Never-Smokers: An Epidemiologic Perspective

    Lung Cancer in Never-Smokers: An Epidemiologic Perspective

    By

    Daniel S.W. Tan, MD, PhD, et al.
    Global Initiatives

    Posted: February 2017 By Chee-Keong Toh, MD, and Daniel SW Tan, MD The recent decade has seen much interest in lung cancer in never-smokers (LCNS), in most part attributed to the expanding number of therapeutically tractable alterations enriched within this clinical phenotype.1 However, equally relevant are studies directed at understanding the etiology of LCNS, for…

  • FDA Corner – Interview with Amy Mckee, MD

    FDA Corner – Interview with Amy Mckee, MD

    By

    Regulatory Agency Perspective

    Posted: February 2017 BY Erik J. Maclaren, PhD Breakthrough Therapy Designation and Mechanisms of Expedited Review The U.S. Food and Drug Administration (FDA) is responsible for reviewing the evidence of safety and efficacy for all new drugs before they can be made available to patients. Increasing the efficiency and speed of the approval process for…

  • NCI Corner – Interview with Shakun Malik, MD

    NCI Corner – Interview with Shakun Malik, MD

    By

    Regulatory Agency Perspective

    Posted: February 2017 By Erik J. Maclaren, PhD 2017 Mesothelioma Clinical Trials Planning Meeting Malignant mesothelioma is one of the most difficult cancers to control using existing therapies. Due to the rarity of this disease, randomized trials for potential new treatments are lacking. In order to facilitate clinical trials in patients with malignant mesothelioma, the…

  • Lung Cancer and Smoking Cessation: Opportunities for Progress

    Lung Cancer and Smoking Cessation: Opportunities for Progress

    By

    Regulatory Agency Perspective

    By Stephanie R. Land, PhD Tobacco cessation assistance, imperative for tobacco users who seek medical care,1 takes on even greater urgency for individuals who are undergoing cancer screening or treatment. Cigarette smoking and other tobacco use in these settings raise important questions about how tobacco use affects patients and their cancer therapy, how to design…

  • Today’s Age of Drug Development Q & A with Kapil Dhingra, MD

    Today’s Age of Drug Development Q & A with Kapil Dhingra, MD

    By

    Global Initiatives

    By Cynthia L. Kryder, MS IASLC Lung Cancer News recently spoke with Kapil Dhingra, MD, of KAPital Consulting LLC in Sparta, New Jersey, about oncologic drug development and the challenges and opportunities to anticipate in the future. Q: What are the perils and pitfalls of oncologic drug development in the new millennium? A: I don’t…

  • Next-Generation Sequencing Across the World: Reports from France, Germany, and China

    Next-Generation Sequencing Across the World: Reports from France, Germany, and China

    By

    Global Initiatives

    Next-generation sequencing (NGS) technology has revolutionized genomic and genetic research as it fulfills its potential to tailor the treatment of cancer patients in general and non-small cell lung cancer (NSCLC) patients in particular to their cancer genome alterations. The role of NGS in drug development and clinical trials varies worldwide in response to regional and…

  • FDA Corner – Interview with Reena Philip, PHD, and Eunice Lee, PHD

    FDA Corner – Interview with Reena Philip, PHD, and Eunice Lee, PHD

    By

    Regulatory Agency Perspective

    By Erik J. MacLaren, PhD Liquid Biopsy Testing On June 1, 2016, the U.S. Food and Drug Administration (FDA) approved the use of the cobas EGFR Mutation Test v2 to detect mutations in the epidermal growth factor receptor (EGFR) gene using patient plasma samples. IASLC Lung Cancer News spoke with Reena Philip, PhD, Director of…

View ILCN Archives

Provider Resources

Popular Articles